Free Trial

ResMed (RMD) Stock Forecast & Price Target

$205.72
-1.08 (-0.52%)
(As of 03:57 PM ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 11 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 5 have given a hold rating, and 6 have given a buy rating for RMD.

Consensus Price Target

$202.80
-1.42% Downside
High Forecast$238.00
Average Forecast$202.80
Low Forecast$165.00

According to the 11 analysts' twelve-month price targets for ResMed, the average price target is $202.80. The highest price target for RMD is $238.00, while the lowest price target for RMD is $165.00. The average price target represents a forecasted downside of -1.42% from the current price of $205.72.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
5 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$202.80$202.80$199.20$263.43
Forecasted Upside-1.42% Downside12.03% Upside12.14% Upside17.72% Upside
Get ResMed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.55
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-1.42% Downside1,208.14% Upside7.55% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/25/2024Oppenheimer
3 of 5 stars
 DowngradeOutperform ➝ Market Perform
6/24/2024Citigroup
3 of 5 stars
M. Chevrier
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
6/24/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$236.00 ➝ $236.00+14.66%
4/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00-6.23%
4/26/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$227.00 ➝ $238.00+29.75%
3/27/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$215.00+9.88%
1/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$175.00 ➝ $180.00-3.41%
1/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$160.00 ➝ $195.00+7.32%
10/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$180.00 ➝ $169.00+21.82%
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%
9/29/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
9/18/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $230.00+56.36%
1/31/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:29 PM ET.

RMD Forecast - Frequently Asked Questions

What is ResMed's forecast for 2024?

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $202.80, with a high forecast of $238.00 and a low forecast of $165.00.

Should I buy or sell ResMed stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.

Does ResMed's stock price have much upside?

According to analysts, ResMed's stock has a predicted upside of 11.69% based on their 12-month stock forecasts.

Has ResMed been downgraded by Wall Street analysts recently?

Over the previous 90 days, ResMed's stock had 2 downgrades by analysts.

What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup, KeyCorp, Needham & Company LLC, Oppenheimer, and Royal Bank of Canada in the past 90 days.

Do Wall Street analysts like ResMed more than its competitors?

Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.55 while the average consensus rating score for "medical" companies is 2.71. Learn more on how RMD compares to other companies.


This page (NYSE:RMD) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners